Literature DB >> 32120035

Molecular epidemiology of Escherichia coli causing bloodstream infections in a centralized Canadian region: a population-based surveillance study.

M S Holland1, D Nobrega2, G Peirano3, C Naugler4, D L Church4, J D D Pitout5.   

Abstract

OBJECTIVES: Escherichia coli is a leading cause of bloodstream infections worldwide, and is responsible for substantial patient morbidity, mortality and healthcare expenditure. Understanding the molecular epidemiology of E. coli will aid in designing superior treatment and prevention strategies.
METHODS: We undertook a population-based surveillance study describing the clinical factors, susceptibility patterns, incidence rates and geographical distribution of sequence types (STs) among E. coli isolates (n = 686) causing incident bloodstream infections in a centralized Canadian region during 2016. STs were identified using a seven-single-nucleotide-polymorphism quantitative PCR (n = 422) and sequencing of certain house-keeping genes (n = 249).
RESULTS: The annual population incidence rate of E. coli bloodstream infections was 48.8/100 000 patient years, and five dominant clones (ST131, ST73, ST69, ST95 and ST1193) accounting for 55% (378/686) of the population were identified, each with a specific geographical distribution within Calgary. ST131 was the most common (overall incidence rate of 10.4/100 000 patient years), an antimicrobial-resistant (AMR) clone affecting mainly the elderly and the very young. ST131 was common among residents in long-term care with an incidence rate of 312.5/100 000 patient years. ST73 was associated with community infections in the elderly, while ST69 and ST95 had increased incidence rates among females. ST1193 was the second most AMR clone and was associated with bloodstream infections in elderly males.
CONCLUSIONS: This study showed that E. coli clones have unique characteristics in a well-defined human population. The elimination of ST131 would substantially decrease the overall incidence rate and AMR burden among E. coli bloodstream infections in the Calgary region, leading to considerable public health benefits.
Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bloodstream infections; Escherichia coli; Molecular epidemiology; Population-based surveillance

Mesh:

Substances:

Year:  2020        PMID: 32120035     DOI: 10.1016/j.cmi.2020.02.019

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  10 in total

Review 1.  Escherichia coli ST1193: Following in the Footsteps of E. coli ST131.

Authors:  Johann D D Pitout; Gisele Peirano; Liang Chen; Rebekah DeVinney; Yasufumi Matsumura
Journal:  Antimicrob Agents Chemother       Date:  2022-06-06       Impact factor: 5.938

2.  The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: a prospective comparative study.

Authors:  Anna Lindblom; Camilla Kiszakiewicz; Erik Kristiansson; Shora Yazdanshenas; Nina Kamenska; Nahid Karami; Christina Åhrén
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

3.  Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.

Authors:  Jesús Sojo-Dorado; Inmaculada López-Hernández; Clara Rosso-Fernandez; Isabel M Morales; Zaira R Palacios-Baena; Alicia Hernández-Torres; Esperanza Merino de Lucas; Laura Escolà-Vergé; Elena Bereciartua; Elisa García-Vázquez; Vicente Pintado; Lucía Boix-Palop; Clara Natera-Kindelán; Luisa Sorlí; Nuria Borrell; Livia Giner-Oncina; Concha Amador-Prous; Evelyn Shaw; Alfredo Jover-Saenz; Jose Molina; Rosa M Martínez-Alvarez; Carlos J Dueñas; Jorge Calvo-Montes; Jose T Silva; Miguel A Cárdenes; María Lecuona; Virginia Pomar; Lucía Valiente de Santis; Genoveva Yagüe-Guirao; María Angeles Lobo-Acosta; Vicente Merino-Bohórquez; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  JAMA Netw Open       Date:  2022-01-04

4.  Prevalence and Molecular Characterization of Fluoroquinolone-Resistant Escherichia coli in Healthy Children.

Authors:  Qiang Zhao; Yueyun Shen; Gang Chen; Yanping Luo; Shenghui Cui; Yaping Tian
Journal:  Front Cell Infect Microbiol       Date:  2021-12-13       Impact factor: 5.293

5.  Antimicrobial Resistance and Molecular Epidemiology of Escherichia coli From Bloodstream Infection in Shanghai, China, 2016-2019.

Authors:  Shuzhen Xiao; Chenyue Tang; Qian Zeng; Yilun Xue; Qing Chen; Erzhen Chen; Lizhong Han
Journal:  Front Med (Lausanne)       Date:  2022-01-10

6.  Genomic insights into the circulation of pandemic fluoroquinolone-resistant extra-intestinal pathogenic Escherichia coli ST1193 in Vietnam.

Authors:  Quynh Nguyen; To Thi Nguyen Nguyen; Phuong Pham; Vinh Chau; Lan Phu Huong Nguyen; Toan Duc Nguyen; Tuyen Thanh Ha; Nhi Thi Quynh Le; Duong Thuy Vu; Stephen Baker; Guy E Thwaites; Maia A Rabaa; Duy Thanh Pham
Journal:  Microb Genom       Date:  2021-12

7.  Drug susceptibility and molecular epidemiology of Escherichia coli in bloodstream infections in Shanxi, China.

Authors:  Yanjun Zhang; Hairu Wang; Yanfang Li; Yabin Hou; Chonghua Hao
Journal:  PeerJ       Date:  2021-10-25       Impact factor: 2.984

8.  Population Dynamics of Escherichia coli Causing Bloodstream Infections over Extended Time Periods.

Authors:  Johann D D Pitout
Journal:  mSphere       Date:  2021-12-22       Impact factor: 4.389

9.  Genomic Epidemiology of Global Carbapenemase-Producing Escherichia coli, 2015-2017.

Authors:  Gisele Peirano; Liang Chen; Diego Nobrega; Thomas J Finn; Barry N Kreiswirth; Rebekah DeVinney; Johann D D Pitout
Journal:  Emerg Infect Dis       Date:  2022-05       Impact factor: 16.126

10.  Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006-20161.

Authors:  Gisele Peirano; Tarah Lynch; Yasufumi Matsumara; Diego Nobrega; Thomas J Finn; Rebekah DeVinney; Johann D D Pitout
Journal:  Emerg Infect Dis       Date:  2020-12       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.